Valeo Pharma Inc (CSE:VPH) (OTCQB:VPHIF) (FSE:VP2), a Canadian specialty pharmaceutical company, announced on Wednesday that the company has qualified to trade on the OTCQB market, which is the venture market in the United States.
The Montreal-based company’s shares have started trading on the OTCQB under the symbol "VPHIF." The company will continue to list its shares on the Canadian Securities Exchange (CSE).
"The listing of our shares on the OTCQB is part of our strategy to broaden our shareholder base with the addition of US institutional and retail investors while increasing liquidity for all our shareholders," said Valeo Pharma CEO Steve Saviuk.
"This is a timely milestone as we continue to launch new products and actively pursue new growth initiatives."
The OTCQB Venture Market is the premiere marketplace for early stage and developing US and international companies and requires companies to be current in their reporting and undergo an annual verification and management certification process.
Valeo is focused on commercializing products for neurodegenerative diseases, oncology and hospital specialty products.
Contact the author Uttara Choudhury at firstname.lastname@example.org
Follow her on Twitter: @UttaraProactive